CHAMPIONS ONCOLOGY, INC. (CSBR) [Rocket]

Overview

CHAMPIONS ONCOLOGY, INC. (CSBR)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/13/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/11/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2023	4	Mendelson Daniel Newman (Director) has filed a Form 4 on CHAMPIONS ONCOLOGY, INC.
10/06/2023	4	Mendelson Daniel Newman (Director) has filed a Form 4 on CHAMPIONS ONCOLOGY, INC.
10/04/2023	4	Mendelson Daniel Newman (Director) has filed a Form 4 on CHAMPIONS ONCOLOGY, INC.
10/04/2023	4	Mendelson Daniel Newman (Director) has filed a Form 4 on CHAMPIONS ONCOLOGY, INC.
09/27/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Apr-30-22	Apr-30-21	Apr-30-20	Apr-30-19	Apr-30-18	Apr-30-17	Apr-30-16	Apr-30-15
Revenues	49.1	41.0	32.1	27.1	20.2	15.4	11.2	8.9
Revenue growth	19.7%	27.8%	18.7%	33.7%	31.3%	37.8%	26.2%	-23.3%
Cost of goods sold	23.6	21.4	17.0	0.0	0.0	0.0	0.0	0.0
Gross profit	25.5	19.6	15.1	27.1	20.2	15.4	11.2	8.9
Gross margin	51.9%	47.7%	47.1%	100.0%	100.0%	100.0%	100.0%	100.0%
Sales and marketing	6.4	5.5	4.2	3.1	2.6	3.3	3.4	4.3
Research and development	9.4	7.2	5.9	4.8	4.4	4.3	4.2	4.8
General and administrative	9.1	6.5	6.6	4.7	4.1	5.0	5.2	5.3
EBIT	0.6	0.4	-1.6	0.3	-1.4	-6.8	-10.3	-13.2
EBIT margin	1.2%	0.9%	-4.9%	1.0%	-6.7%	-44.2%	-92.3%	-149.4%
Pre-tax income	0.6	0.4	-2.0	0.2	-1.4	-6.9	-10.4	-13.0
Income taxes	0.0	0.1	0.1	0.1	0.0	0.0	0.1	0.1
Tax rate	6.0%	17.2%		44.6%
Net income	0.5	0.4	-2.1	0.1	-1.5	-6.9	-10.4	-13.1
Net margin	1.1%	0.9%	-6.5%	0.5%	-7.3%	-44.8%	-93.4%	-148.3%

Diluted EPS	$0.04	$0.02	($0.18)	$0.01	($0.13)	($0.65)	($1.20)	($2.05)
Shares outstanding (diluted)	14.2	14.6	11.8	14.1	11.0	10.7	8.7	6.4

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.